|
Real-time
Euronext Paris
08:37:07 10/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8810 EUR | 0.00% |
|
-0.45% | -8.23% |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
| 09-03 | Transgene jumps 20% on positive cancer vaccine data in early trial | RE |
Company Valuation: Transgene
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.8 | 164.8 | 137.8 | 89.75 | 262.9 | 241.3 | - | - |
| Change | - | -33.52% | -16.38% | -34.86% | 192.89% | -8.21% | - | - |
| Enterprise Value (EV) 1 | 214.9 | 151.4 | 139.4 | 83.48 | 153.1 | 172.1 | 233.6 | 259.9 |
| Change | - | -29.53% | -7.95% | -40.12% | 83.37% | 12.42% | 35.74% | 11.26% |
| P/E | -12.1x | -5.02x | -6.23x | -2.34x | -3.69x | -6.29x | -4x | -9.79x |
| PBR | 3.69x | 4.38x | 8.82x | 5.92x | 1.14x | 2.94x | 11x | -88.1x |
| PEG | - | -0.1x | 0.2x | -0.1x | 0.4x | 0.1x | -0.1x | 0.2x |
| Capitalization / Revenue | 14.2x | 15.9x | 17.4x | 14.1x | 36.5x | 33.5x | 33.5x | 4.22x |
| EV / Revenue | 12.3x | 14.6x | 17.6x | 13.1x | 21.2x | 23.9x | 32.4x | 4.54x |
| EV / EBITDA | -10.2x | -5.37x | -4.9x | -2.43x | -4.54x | -3.95x | -3.33x | -11x |
| EV / EBIT | -9.14x | -5.06x | -4.64x | -2.34x | -4.37x | -3.88x | -3.3x | -8.87x |
| EV / FCF | -6.59x | -6.94x | -1,408x | -3.12x | -1.07x | -4.33x | -3.87x | -10.4x |
| FCF Yield | -15.2% | -14.4% | -0.07% | -32% | -93.4% | -23.1% | -25.9% | -9.66% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.14 | -0.22 | -0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 17.41 | 10.34 | 7.9 | 6.353 | 7.21 | 7.2 | 7.2 | 57.2 |
| EBITDA 1 | -21 | -28.22 | -28.48 | -34.38 | -33.73 | -43.6 | -70.1 | -23.6 |
| EBIT 1 | -23.52 | -29.9 | -30.05 | -35.66 | -35.06 | -44.3 | -70.8 | -29.3 |
| Net income 1 | -19.54 | -32.8 | -22.33 | -33.97 | -37.52 | -38.2 | -61.6 | -25.3 |
| Net Debt 1 | -32.93 | -13.31 | 1.629 | -6.274 | -109.8 | -69.2 | -7.7 | 18.6 |
| Reference price 2 | 2.5400 | 1.6580 | 1.3700 | 0.6800 | 0.9600 | 0.8810 | 0.8810 | 0.8810 |
| Nbr of stocks (in thousands) | 97,576 | 99,370 | 100,566 | 131,990 | 273,827 | 273,882 | - | - |
| Announcement Date | 16/03/22 | 16/03/23 | 27/03/24 | 27/03/25 | 24/03/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29x | 23.9x | -3.95x | - | 280M | |
| 20.12x | 7.11x | 14.28x | 1.48% | 68.52B | |
| 32.41x | 9.38x | 45.24x | 0.04% | 62.88B | |
| -78.84x | 15.22x | -73.41x | -.--% | 28.13B | |
| 29.47x | 6.3x | 16.34x | -.--% | 25.56B | |
| -14.82x | 5.45x | -6.85x | -.--% | 24.65B | |
| 26.99x | 5.06x | 16.84x | -.--% | 19.81B | |
| 50.73x | 18.74x | 38.02x | 0.3% | 17.69B | |
| 1267.09x | 36.54x | 797.35x | -.--% | 14.66B | |
| 18.02x | 5.37x | 12.54x | -.--% | 14.45B | |
| Average | 134.49x | 13.31x | 85.64x | 0.2% | 27.66B | |
| Weighted average by Cap. | 79.00x | 10.31x | 53.80x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TNG Stock
- Valuation Transgene
Select your edition
All financial news and data tailored to specific country editions
